| Dr Mandakolathur R Murali, MD | |
|
55 Fruit Street, Cox 201, Boston, MA 02114-3117 | |
| (617) 726-3850 | |
| (617) 726-3847 |
| Full Name | Dr Mandakolathur R Murali |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 52 Years |
| Location | 55 Fruit Street, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891718250 | NPI | - | NPPES |
| 213978 | Other | MA | TUFTS HEALTH PLAN |
| 0169366 | Medicaid | MA | |
| J24730 | Other | MA | BCBS MA |
| Facility Name | Location | Facility Type |
|---|---|---|
| Massachusetts General Hospital | Boston, MA | Hospital |
| Martha's Vineyard Hospital Inc | Oak bluffs, MA | Hospital |
| Brigham And Women's Hospital | Boston, MA | Hospital |
| Massachusetts Eye And Ear Infirmary - | Boston, MA | Hospital |
| Nantucket Cottage Hospital | Nantucket, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Massachusetts General Physicians Organization Inc | 2466365820 | 3085 |
News Archive
The results of a phase 2 clinical trial featuring a SARS-CoV-2 recombinant protein vaccine developed by GlaxoSmithKline are reported, demonstrating a favorable immune response amongst both naïve and non-naïve adults with an acceptable safety profile.
An international group of scientists has taken the first step on the road to targeting radiotherapy dosage to individual patients by means of their genetic characteristics, a radiation oncologist told Europe's largest cancer congress, ECCO 15 - ESMO 34, in Berlin today (Thursday September 24). Professor Dirk de Ruysscher, from Maastricht University Medical Centre, Maastricht, The Netherlands, said that his team's work might provide the basis for personalised radiotherapy in which, with a simple blood test, doctors may be able to select the optimal radiation dose for a particular patient.
An analysis of a school behavior strategy-known as School-Wide Positive Behavioral Interventions and Supports (SWPBIS)-found that these types of programs significantly reduced children's aggressive behaviors and office discipline referrals, as well as improved problems with concentration and emotional regulation.
Black women with breast cancer were found to be three times more likely than their white counterparts to delay treatment for more than 90 days - a time delay associated with increased deaths from the disease, according to a new study led by researchers at Georgetown Lombardi Comprehensive Cancer Center.
› Verified 5 days ago
| Entity Name | Massachusetts General Physicians Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801874573 PECOS PAC ID: 2466365820 Enrollment ID: O20031111000434 |
News Archive
The results of a phase 2 clinical trial featuring a SARS-CoV-2 recombinant protein vaccine developed by GlaxoSmithKline are reported, demonstrating a favorable immune response amongst both naïve and non-naïve adults with an acceptable safety profile.
An international group of scientists has taken the first step on the road to targeting radiotherapy dosage to individual patients by means of their genetic characteristics, a radiation oncologist told Europe's largest cancer congress, ECCO 15 - ESMO 34, in Berlin today (Thursday September 24). Professor Dirk de Ruysscher, from Maastricht University Medical Centre, Maastricht, The Netherlands, said that his team's work might provide the basis for personalised radiotherapy in which, with a simple blood test, doctors may be able to select the optimal radiation dose for a particular patient.
An analysis of a school behavior strategy-known as School-Wide Positive Behavioral Interventions and Supports (SWPBIS)-found that these types of programs significantly reduced children's aggressive behaviors and office discipline referrals, as well as improved problems with concentration and emotional regulation.
Black women with breast cancer were found to be three times more likely than their white counterparts to delay treatment for more than 90 days - a time delay associated with increased deaths from the disease, according to a new study led by researchers at Georgetown Lombardi Comprehensive Cancer Center.
› Verified 5 days ago
| Entity Name | The General Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023049236 PECOS PAC ID: 6507803806 Enrollment ID: O20080313000351 |
News Archive
The results of a phase 2 clinical trial featuring a SARS-CoV-2 recombinant protein vaccine developed by GlaxoSmithKline are reported, demonstrating a favorable immune response amongst both naïve and non-naïve adults with an acceptable safety profile.
An international group of scientists has taken the first step on the road to targeting radiotherapy dosage to individual patients by means of their genetic characteristics, a radiation oncologist told Europe's largest cancer congress, ECCO 15 - ESMO 34, in Berlin today (Thursday September 24). Professor Dirk de Ruysscher, from Maastricht University Medical Centre, Maastricht, The Netherlands, said that his team's work might provide the basis for personalised radiotherapy in which, with a simple blood test, doctors may be able to select the optimal radiation dose for a particular patient.
An analysis of a school behavior strategy-known as School-Wide Positive Behavioral Interventions and Supports (SWPBIS)-found that these types of programs significantly reduced children's aggressive behaviors and office discipline referrals, as well as improved problems with concentration and emotional regulation.
Black women with breast cancer were found to be three times more likely than their white counterparts to delay treatment for more than 90 days - a time delay associated with increased deaths from the disease, according to a new study led by researchers at Georgetown Lombardi Comprehensive Cancer Center.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mandakolathur R Murali, MD Po Box 9142, Mass General Physician Organization, Charlestown, MA 02129-9142 Ph: (617) 726-3850 | Dr Mandakolathur R Murali, MD 55 Fruit Street, Cox 201, Boston, MA 02114-3117 Ph: (617) 726-3850 |
News Archive
The results of a phase 2 clinical trial featuring a SARS-CoV-2 recombinant protein vaccine developed by GlaxoSmithKline are reported, demonstrating a favorable immune response amongst both naïve and non-naïve adults with an acceptable safety profile.
An international group of scientists has taken the first step on the road to targeting radiotherapy dosage to individual patients by means of their genetic characteristics, a radiation oncologist told Europe's largest cancer congress, ECCO 15 - ESMO 34, in Berlin today (Thursday September 24). Professor Dirk de Ruysscher, from Maastricht University Medical Centre, Maastricht, The Netherlands, said that his team's work might provide the basis for personalised radiotherapy in which, with a simple blood test, doctors may be able to select the optimal radiation dose for a particular patient.
An analysis of a school behavior strategy-known as School-Wide Positive Behavioral Interventions and Supports (SWPBIS)-found that these types of programs significantly reduced children's aggressive behaviors and office discipline referrals, as well as improved problems with concentration and emotional regulation.
Black women with breast cancer were found to be three times more likely than their white counterparts to delay treatment for more than 90 days - a time delay associated with increased deaths from the disease, according to a new study led by researchers at Georgetown Lombardi Comprehensive Cancer Center.
› Verified 5 days ago
Dr. David H. Sachs, M.D. Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: Bldg. 149-9019, 13th Street, Boston, MA 02466 Phone: 617-726-4065 Fax: 617-726-4067 | |
Dr. Anne Esther Goldfeld, M.D. Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 800 Huntington Ave, Boston, MA 02115 Phone: 617-278-3351 Fax: 617-278-3454 | |
Dr. Sachin Niranjan Baxi, M.D. Allergy & Immunology Medicare: Medicare Enrolled Practice Location: 300 Longwood Ave, Fegan 6, Boston, MA 02115 Phone: 617-919-2489 Fax: 617-730-0310 | |
Dr. Richard Arthur Moscicki, MD Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 15 Parkman St, Allergy Associates Wac 626, Boston, MA 02114 Phone: 617-726-3764 Fax: 617-252-7694 | |
Abduarahmn Almutairi, MD Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 300 Longwood Ave, Boston, MA 02115 Phone: 617-355-6117 | |
John L Ohman, MD Allergy & Immunology Medicare: Medicare Enrolled Practice Location: 750 Washington St, Nemc Box 30, Boston, MA 02111 Phone: 617-636-5000 Fax: 617-636-4843 | |
Dr. Paul J. Maglione, MD, PHD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 725 Albany St, Shapiro 9 Suite B, Boston, MA 02118 Phone: 617-638-7480 |